Silvercrest Asset Management Group LLC Has $2.19 Million Stake in Exagen Inc. (NASDAQ:XGN)

Silvercrest Asset Management Group LLC trimmed its position in shares of Exagen Inc. (NASDAQ:XGN) by 1.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 535,017 shares of the company’s stock after selling 5,871 shares during the period. Silvercrest Asset Management Group LLC owned 3.03% of Exagen worth $2,194,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in XGN. Corient Private Wealth LLC acquired a new position in shares of Exagen in the fourth quarter valued at $45,000. Virtu Financial LLC acquired a new position in shares of Exagen in the fourth quarter valued at $46,000. Marshall Wace LLP acquired a new position in shares of Exagen in the fourth quarter valued at $66,000. Northern Trust Corp increased its holdings in shares of Exagen by 16.7% in the fourth quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock valued at $75,000 after purchasing an additional 2,630 shares during the last quarter. Finally, Palumbo Wealth Management LLC increased its holdings in shares of Exagen by 13.5% in the fourth quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company’s stock valued at $355,000 after purchasing an additional 10,340 shares during the last quarter. 75.25% of the stock is currently owned by institutional investors and hedge funds.

Exagen Trading Up 5.3%

XGN opened at $6.33 on Tuesday. Exagen Inc. has a twelve month low of $1.71 and a twelve month high of $7.20. The company has a 50-day simple moving average of $4.87 and a 200 day simple moving average of $4.26. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54. The stock has a market capitalization of $134.83 million, a price-to-earnings ratio of -6.73 and a beta of 1.50.

Exagen (NASDAQ:XGN) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, hitting the consensus estimate of ($0.20). Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. The business had revenue of $15.50 million during the quarter, compared to analysts’ expectations of $14.55 million. During the same quarter in the prior year, the business posted ($0.19) earnings per share. Analysts predict that Exagen Inc. will post -0.88 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

XGN has been the subject of a number of recent research reports. UBS Group reissued an “overweight” rating on shares of Exagen in a research report on Thursday. Cantor Fitzgerald reduced their target price on shares of Exagen from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Thursday, May 15th. William Blair reissued an “outperform” rating on shares of Exagen in a research report on Wednesday, March 12th. BTIG Research reissued a “buy” rating on shares of Exagen in a research report on Wednesday, May 7th. Finally, Canaccord Genuity Group boosted their target price on shares of Exagen from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Tuesday, May 13th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $7.50.

Exagen Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).